Gonadorelin
| Clinical data | |
|---|---|
| Trade names | Factrel, HRF, Kryptocur, Lutrelef, Lutrepulse, Relefact, others | 
| Other names | Abbott 41070; AY-24031; Hoe-471; RU-19847 | 
| Routes of administration | intravenous, subcutaneous | 
| Drug class | GnRH analogue; GnRH agonist; Progonadotropin | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Metabolism | Hydrolysis | 
| Elimination half-life | 10–40 minutes | 
| Identifiers | |
| 
 | |
| CAS Number | 
 | 
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.046.852 | 
| Chemical and physical data | |
| Formula | C55H75N17O13 | 
| Molar mass | 1182.311 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
Gonadorelin is a gonadotropin-releasing hormone agonist (GnRH agonist) which is used in fertility medicine and to treat amenorrhea and hypogonadism. It is also used in veterinary medicine. The medication is a form of the endogenous GnRH and is identical to it in chemical structure. It is given by injection into a blood vessel or fat or as a nasal spray.